N/A N=6

VircapSeq Virus Detection in Sézary Syndrome

Lymphoma, T-Cell, Cutaneous · Sézary Syndrome

Bottom Line

View on ClinicalTrials.gov: NCT02836886 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2024

Primary outcome: Primary: Number of Participants With Viral Sequences Present in Malignant T Cells of Patients With Sézary Syndrome — 6 Participants

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: —
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Columbia University
Primary completion: Oct 2016

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants With Viral Sequences Present in Malignant T Cells of Patients With Sézary Syndrome	6	—

Summary

This study will be using this technique, called "VirCapSeq-VERT" to analyze the white blood cells of patients with Sézary syndrome. This could provide the foundation for future studies looking to understand the role that viruses play in the origin of Sézary syndrome. This could have important implications for the future development of new and effective therapies for the disease.

Eligibility Criteria

Inclusion Criteria

Patients with Sézary syndrome diagnosed according to the WHO-EORTC classification.

Exclusion Criteria

Pregnant patients.
Patients with known anemia with documented <7.5 mg/dL.
Patients who are unable to give informed consent.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02836886). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.